Table 6.
Progression of normal thyroid status to subclinical hypothyroidism and of subclinical hypothyroidism to overt hypothyroidism
| Reference | Place | Age/follow-up | Antithyroid peroxidase | Evolution to overt disease | Observations |
|---|---|---|---|---|---|
| Parle et al77 | United Kingdom | Mean age men 70.1 (6.1) years; mean age men women 70.7 (7.3) years | Incidence No information |
TSH between 5–10 mIU/l/no antibodies: 2/28: 7.1% TSH between 5–10 mIU/l/positive antibodies: 5/27: 18.5% TSH > 10 mIU/L/no antibodies: 1/4: 25% TSH > 10 mIU/L/positive antibodies: 5/14: 35.7% |
Evaluated progression of subclinical hypothyroidism to overt disease according to TSH and antithyroid antibodies levels |
| Vanderpump et al2 | United Kingdom | 86.2% of sample with >45 years | Incidence Women 45–54, 15.6% 55–64, 20.8% 65–74, 15.8% 75–84, 18.8% ≥85, 10.0% Total, 17.3 Men 45–54, 3.7% 55–64, 9.5% 65–74, 5.8% 75–84, 11.5% ≥85, 11.1% Total, 6.6 |
Women with only TSH > 6 mIU/L at baseline: OR, 8 (95% CI, 3–20) with only positive antithyroid antibodies at baseline: OR, 8 (95% CI, 5–15) with TSH > 6 mIU/L and positive antithyroid antibodies at baseline: 38 (95% CI, 22–65) with only TSH > 6 mIU/L at baseline: OR, 44 (95% CI, 19–104) with only positive antithyroid antibodies at baseline: OR, 25 (95% CI, 10–63) with TSH > 6 mIU/L and positive antithyroid antibodies at baseline: 173 (95% CI, 81–370) |
Evaluated progression of subclinical hypothyroidism to overt disease |
| Gopinath et al25 | Australia | ≥55 years 5 years follow-up |
No information | Subclinical hypothyroidism in women (using men as a reference): OR, 3.71 (95% CI, 1.05–13.11) TSH mIU/L (as a continuous variable): OR, 3.94 (95% CI, 2.21–7.04) Overt hypothyroidism in women (using men as a reference): 2.57 (95% CI, 1.01–6.54) TSH mIU/L (as a continuous variable): 4.13 (95% CI, 2.55–6.71) Fasting blood glucose (mmoL/L): 1.19 (95% CI, 1.00–1.42) BMI ≥ 30 kg/m2 (using BMI < 30 kg/m2 as a reference): 4.05 (1.74–9.41) White cell count (×109/l) as a continuous variable: 1.19 (1.01–1.40) |
Evaluated progression of normal thyroid status to subclinical and overt hypothyroidism |
Abbreviations: TSH, thyrotropin or thyroid stimulating hormone; FT4, free-thyroxine; OR, odds ratio; 95% CI, 95% confidence interval; BMI, body mass index.